Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AAUS vs RADX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RADX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–3 Matrix Metrics)

RADX Overall Winner 6-Pillar Tally: AAUS 1 – 3 RADX (2 Tie) Matrix Metrics: AAUS 3 – 5 RADX

As of Nov 20, 2026, Radiopharm Theranostics Limited (RADX) is the stronger overall head-to-head candidate over AAUS (AAUS) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAUS carries a Unified Composite Score of 43.4/100 (HOLD) at $55.08 (N/M Forward P/E, N/A operating margin), whereas RADX carries 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin).

  • Composite vs. Pillar Nuance: While AAUS currently prints a higher short-term Unified Composite Score (43.4/100 HOLD vs. RADX 41.1/100 SELL), RADX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-411.6% vs. N/A operating margin) and revenue trajectory (-36.9% vs. N/A YoY).
  • Technical & Structure Timing Caution: AAUS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.8); meanwhile RADX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AAUS vs RADX
AAUS US Equity
AAUS
Institutional Equity
$55.08
-3.9% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.97β · 24% Vol
Unified Composite Score
43.4 / 100 HOLD
Tech 28.0 Fund 48.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.0%), weak momentum, RSI 25
RSI-14: 24.8 · SMA20: $59.94 · SMA50: $61.14
RADX NASDAQ Head-to-Head Winner
Radiopharm Theranostics Limited American Depositary Shares
Pharmaceutical Preparations
$0.63
-6.33% 1D
Market Cap $10.6M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 0.52β · 109% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.5%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.86 · SMA50: $1.15

6-Pillar Scorecard Institutional Category Breakdown (AAUS 1 – 3 RADX)

Columns: Metric · AAUS · RADX
1. Valuation Multiples RADX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.8x
2. Growth & Scale RADX
Revenue Growth (YoY) N/A -36.9%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $13M
Market Cap N/A $10.6M
3. Profitability & Quality RADX
Gross Margin N/A N/A
Operating Margin N/A -411.6%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -174.7%
4. Balance Sheet & Cash Flow AAUS
Cash Generation (TTM) N/A -$50M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $1.48 Book/Sh · -174.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AAUS (3) vs RADX (5)
Institutional Metric AAUS RADX Criterion Row Edge
Market Capitalization
Scale
N/A $10.6M Larger Scale RADX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -36.9% Higher Growth RADX
Operating Margin (TTM)
Profitability
N/A -411.6% Higher Margin RADX
Net Profit Margin
Profitability
N/A 0.0% Higher Margin RADX
Return on Equity (ROE)
Capital Efficiency
N/A -174.7% Higher ROE RADX
52-Week Range Position
Momentum
32% ($51–$64) 0% ($1–$16) Stronger Trend AAUS
Beta / 30D Volatility
Risk Regime
0.97β · 24% Vol 0.52β · 109% Vol Lower Realized Risk AAUS
Unified Institutional Score
Composite Signal
43.4 / 100 (HOLD) 41.1 / 100 (SELL) Higher Composite AAUS
Trailing 12M Revenue (USD)
Operating Scale
N/A $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$50M EBITDA ($1.48 Book/Sh · -174.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AAUS +23.4 pp
AAUS: -10.24% · RADX: -33.64%
3M Horizon AAUS +64.17 pp
AAUS: -9.99% · RADX: -74.16%
6M Horizon AAUS +78.94 pp
AAUS: -7.3% · RADX: -86.24%
1Y Horizon AAUS +88.19 pp
AAUS: +2.15% · RADX: -86.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAUS vs RADX. Trailing 12-month operating profitability (AAUS N/A vs RADX -411.6%) and valuation multiples (AAUS N/M vs RADX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AAUS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
RADX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross MarginN/A
Op. Margin-411.6%
ROE / Fwd P/E-174.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AAUS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AAUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RADX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RADX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AAUS Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RADX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.6M market capitalization and -411.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AAUS vs RADX Key Questions & Quantitative Answers

As of Nov 20, 2026, Radiopharm Theranostics Limited (RADX) is the stronger overall head-to-head candidate over AAUS (AAUS) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAUS carries a Unified Composite Score of 43.4/100 (HOLD) at $55.08 (N/M Forward P/E, N/A operating margin), whereas RADX carries 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin). Composite vs. Pillar Nuance: While AAUS currently prints a higher short-term Unified Composite Score (43.4/100 HOLD vs. RADX 41.1/100 SELL), RADX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-411.6% vs. N/A operating margin) and revenue trajectory (-36.9% vs. N/A YoY). Technical & Structure Timing Caution: AAUS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.8); meanwhile RADX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RADX leads the Growth & Scale pillar: AAUS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with RADX at -36.9% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (N/A gross margin, -411.6% operating margin). On trailing 12-month operating scale, AAUS generates N/A in USD-normalized revenue versus $13M for RADX. In operating R&D and SG&A reinvestment, AAUS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RADX.

RADX screens cheaper on headline valuation multiples. AAUS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas RADX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AAUS (N/A ROE) versus RADX (-174.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AAUS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.97β · 24% Vol realized risk). By comparison, RADX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.52β · 109% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.